

March 15, 1993

Dear Friends:

I hope that your trip back to Moscow was not too unpleasant and that you have now fully recovered from your jet lag. May I say how delighted we all were at Alliance that you were able to visit us and I am sure that our future cooperation will be profitable from both sides.

Here enclosed you will find a number of documents. First, there are two documents that need to be signed for the opening of your bank account. We also need to have an official paper which, in this country, is known as "Articles of Incorporation." This is an official paper to say that a company has been officially created as a company and this means that it is able to have a company bank account. I presume there must be some document that you would be able to produce (preferably translated into English!). If it is not possible to provide such a document, then you would be able to have a bank account with access to that account by signature of one, two or more people signing on bank documents.

Also enclosed you will find documents relating to our communications with the FDA for *LiquiVent*<sup>TM</sup>. A copy of the document requesting Sub Part E Status (you may remember that this is a special status granted for important new drugs to treat severe life threatening or debilitating diseases and implies that the FDA will assist with rapid transit of this drug through the regulatory process) is included. Also included is a copy of the minutes of the meeting subsequently held with the FDA in Washington.


The projection slide is from Hal DeLong and shows details of our various products and gives an indication of how far advanced they are. Also included in this packet are brief reports of biological testing that we have performed with your emulsion, and contains data on fever testing, the effect on thrombocytes and particle size analysis. **It would seem that you have a very good emulsion. We are particularly impressed with the very low particle sizes that you are able to obtain.**

We look forward to receiving reports from you on your evaluation of cytotoxicity of the perflubron samples that we gave you. We are also particularly interested in the detection of impurities in these samples and the identification of which impurities might be responsible for the toxicity. You were also, I believe, going to carry out fluoride ion testing on our emulsion and carry out some tests on the phospholipid samples that we provided for you. As you know, we are particularly interested in obtaining supplies of perfluorochemicals from you and are anxious to obtain high purity perflubron and perfluorodecalin. You were also going to look into the possibility of obtaining extremely cheap fluorocarbon. (It does not really matter what the chemical constitution is providing - it is cheap!)

Enclosed are photos that were taken during our desert trip that I thought you might like to have.

I look forward to hearing from you and to meeting you all again as soon as possible, maybe in June.

Yours sincerely,



N. Simon Faithfull, M.D., Ph.D.  
Vice President, Medical Research

ПЕРЕВОД ФРАГМЕНТА ПИСЬМА,  
полученного 15 марта 1993 г. от американской фармацевтической корпорации "Альянс" (ведущая корпорация в мире, выпускающая перфторуглеродные кровезаменители)

- перевод четвертого абзаца.....Сообщение о биологических испытаниях, которые мы провели с Вашей эмульсией, они содержат данные проверки на появление температуры, влияние на тромбоциты и анализ размеров частиц. Кажется, у Вас очень хорошая эмульсия. Особенно нас поразила очень маленький размер частиц, который Вы можете получить.

Вице-президент  
"Альянса"  
доктор медицины

С. Файтфул